ALUR vs BRTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALUR exhibits severe financial distress with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability, collapsing revenue growth, and negative ROA (-71.87%) signal high distress risk. Despite a gross margin of 60.99%, the company is losing money at an accelerating rate, with a -187.87% profit margin and -362.30% operating margin. The stock trades at a deeply discounted price of $0.53, but this reflects a market pricing in failure rather than value. Analysts have a target of $5.50, but with no consensus recommendation and a 5-year return of -99.8%, the outlook remains bleak.
BRTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ALUR vs BRTX: Head-to-Head Comparison
This page compares Allurion Technologies Inc. (ALUR) and BioRestorative Therapies, Inc. (BRTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.